line
Japanese Society for Palliative Medicine
News Letter No.79
日本緩和医療学会ニューズレター
May 2018  79
Journal Watch
緩和ケアに関する論文レビュー
名古屋大学大学院 医学系研究科 看護学専攻 基礎・臨床看護学講座  佐藤 一樹
対象雑誌:N Engl J Med, Lancet, Lancet Oncol, JAMA, JAMA Intern Med, JAMA Oncol, BMJ, Ann Intern Med, J Clin Oncol, Ann Oncol, Eur J Cancer, Br J Cancer, Cancer

対象期間:2017年12月〜2018年2月刊行分

いわゆる“トップジャーナル”に掲載された緩和ケアに関する最新論文を広く紹介します。

【N Engl J Med. 2017;377(23-26), 2018;378(1-8)】
なし

【Lancet. 2017; 390(10111-10114), 2018;391(10115-
なし

【Lancet Oncol. 2017;18(12), 2018;19(1-2)
1.20-39歳成人のがん罹患と予後に関する2012年の国際疫学データ
Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F. Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. Lancet Oncol. 2017;18(12):1579-89. PMID 29111259.
2.妊娠性絨毛性疾患での健康関連QOLの総説
Ireson J, Jones G, Winter MC, Radley SC, Hancock BW, Tidy JA. Systematic review of health-related quality of life and patient-reported outcome measures in gestational trophoblastic disease: a parallel synthesis approach. Lancet Oncol. 2018;19(1):e56-e64. PMID 29304364.

【JAMA. 2017;318(21-24, 2018;319(1-8)
3.常勤と臨時アルバイトの内科医での入院後死亡リスクの比較
Blumenthal DM, Olenski AR, Tsugawa Y, Jena AB. Association Between Treatment by Locum Tenens Internal Medicine Physicians and 30-Day Mortality Among Hospitalized Medicare Beneficiaries. JAMA. 2017;318(21):2119-29. PMID 29209722.
4.高齢者の骨折とカルシウムやビタミンDとの関連
Zhao JG, Zeng XT, Wang J, Liu L. Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis. JAMA. 2017;318(24):2466-82. PMID 29279934.

【JAMA Intern Med. 2017;177(12), 2018;178(1-2)
5.米国のかかりつけ医のがんサバイバーケアのエスノグラフィー
Rubinstein EB, Miller WL, Hudson SV, Howard J, O'Malley D, Tsui J, et al. Cancer Survivorship Care in Advanced Primary Care Practices: A Qualitative Study of Challenges and Opportunities. JAMA Intern Med. 2017;177(12):1726-32. PMID 28973067.
6.終末期医療の質の人種間での比較(短報)
Sharma RK, Freedman VA, Mor V, Kasper JD, Gozalo P, Teno JM. Association of Racial Differences With End-of-Life Care Quality in the United States. JAMA Intern Med. 2017;177(12):1858-60. PMID 29052697.
7.院内緩和ケアチームの紹介患者の紹介理由と患者の特徴の関連
Bischoff K, O'Riordan DL, Marks AK, Sudore R, Pantilat SZ. Care Planning for Inpatients Referred for Palliative Care Consultation. JAMA Intern Med. 2018;178(1):48-54. PMID 29159371.
8.オピオイド処方者の同居人への新規オピオイド処方のリスク
Seamans MJ, Carey TS, Westreich DJ, Cole SR, Wheeler SB, Alexander GC, et al. Association of Household Opioid Availability and Prescription Opioid Initiation Among Household Members. JAMA Intern Med. 2018;178(1):102-9. PMID 29228098.
9.ナーシングホーム居住者での緩和ケアの適格者の特徴とQOL評価(短報)
Stephens CE, Hunt LJ, Bui N, Halifax E, Ritchie CS, Lee SJ. Palliative Care Eligibility, Symptom Burden, and Quality-of-Life Ratings in Nursing Home Residents. JAMA Intern Med. 2018;178(1):141-2. PMID 29159368.
10.終末期腎疾患での定期的な血液透析と緊急時のみの血液透析での予後と医療の比較
Cervantes L, Tuot D, Raghavan R, Linas S, Zoucha J, Sweeney L, et al. Association of Emergency-Only vs Standard Hemodialysis With Mortality and Health Care Use Among Undocumented Immigrants With End-stage Renal Disease. JAMA Intern Med. 2018;178(2):188-95. PMID 29255898.
11.米国での2002-2015年のガバペンチン使用者の特徴(短報)
Johansen ME. Gabapentinoid Use in the United States 2002 Through 2015. JAMA Intern Med. 2018;178(2):292-4. PMID 29297045.

【JAMA Oncol. 2017;3(12), 2018;4(1-2)
12.非進行期大腸がんでの炎症反応と筋肉量減少と予後の関連
Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, et al. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study. JAMA Oncol. 2017;3(12):e172319. PMID 28796857.
13.経口化学療法の安全性と質の改善に関するシステマティックレビュー
Zerillo JA, Goldenberg BA, Kotecha RR, Tewari AK, Jacobson JO, Krzyzanowska MK. Interventions to Improve Oral Chemotherapy Safety and Quality: A Systematic Review. JAMA Oncol. 2018;4(1):105-17. PMID 28570732.
14.頭頚部がん患者の死因ががん以外となる関連要因(短報)
Simpson MC, Massa ST, Boakye EA, Antisdel JL, Stamatakis KA, Varvares MA, et al. Primary Cancer vs Competing Causes of Death in Survivors of Head and Neck Cancer. JAMA Oncol. 2018;4(2):257-9. PMID 29285537.

【BMJ 2017 359(8132-8134), 2018;360(8135-8142)
15.術後の新規オピオイド処方での過剰摂取や誤用の関連要因
Brat GA, Agniel D, Beam A, Yorkgitis B, Bicket M, Homer M, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. BMJ. 2018;360:j5790. PMID 29343479.

【Ann Intern Med. 2017;167(5-10), 2018;168(1-4)
16.外来でのオピオイド過剰投与に対するナロキソンでの対応方法のシステマティックレビュー
Chou R, Korthuis PT, McCarty D, Coffin PO, Griffin JC, Davis-O'Reilly C, et al. Management of Suspected Opioid Overdose With Naloxone in Out-of-Hospital Settings: A Systematic Review. Ann Intern Med. 2017;167(12):867-75. PMID 29181532.
17.2006-2015年のメディケアでのオピオイド処方の制限(短報)
Samuels EA, Ross JS, Dhruva SS. Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015. Ann Intern Med. 2017;167(12):895-6. PMID 29052693.
18.オピオイド使用障害治療の費用対効果
Krebs E, Enns B, Evans E, Urada D, Anglin MD, Rawson RA, et al. Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California. Ann Intern Med. 2018;168(1):10-9. PMID 29159398.
19.質の高い緩和ケア研究のためのポイント(IDEAS AND OPINIONS)
Courtright KR, Cassel JB, Halpern SD. A Research Agenda for High-Value Palliative Care. Ann Intern Med. 2018;168(1):71-2. PMID 29132161.
20.マリファナ使用の心血管リスクのレビュー
Ravi D, Ghasemiesfe M, Korenstein D, Cascino T, Keyhani S. Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes: A Systematic Review. Ann Intern Med. 2018;168(3):187-94. PMID 29357394.

【J Clin Oncol. 2017;35(34-36), 2018;36(1-6),
21.オピオイド誘発性便秘に対するナルデメジンの第III相試験
Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, et al. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. J Clin Oncol. 2017;35(34):3859-66. PMID 28968171.
22.乳がん骨転移の骨関連事象に対するゾレドロン酸の投与間隔とデノスマブの費用対効果
Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, et al. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). J Clin Oncol. 2017;35(35):3949-55. PMID 29023215.
23.転移性乳がんでの骨修飾薬に関するASCOガイドラインの更新
Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, et al. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol. 2017;35(35):3978-86. PMID 29035643.
24.がん再発不安に対する心理社会的介入の無作為化比較試験(ConquerFear試験)
Butow PN, Turner J, Gilchrist J, Sharpe L, Smith AB, Fardell JE, et al. Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence. J Clin Oncol. 2017;35(36):4066-77. PMID 29095681.
25.がん根治術後のオピオイドの継続処方とその要因
Lee JS, Hu HM, Edelman AL, Brummett CM, Englesbe MJ, Waljee JF, et al. New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery. J Clin Oncol. 2017;35(36):4042-9. PMID 29048972.
26.若年男性がん患者の妊孕性保存の利用とその要因
Klosky JL, Wang F, Russell KM, Zhang H, Flynn JS, Huang L, et al. Prevalence and Predictors of Sperm Banking in Adolescents Newly Diagnosed With Cancer: Examination of Adolescent, Parent, and Provider Factors Influencing Fertility Preservation Outcomes. J Clin Oncol. 2017;35(34):3830-6. PMID 28976795.
27.高齢乳がん患者の予後に対する精神疾患の影響
Iglay K, Santorelli ML, Hirshfield KM, Williams JM, Rhoads GG, Lin Y, et al. Impact of Preexisting Mental Illness on All-Cause and Breast Cancer-Specific Mortality in Elderly Patients With Breast Cancer. J Clin Oncol. 2017;35(36):4012-8. PMID 28934000.
28.医師と患者での予後の話し合いによる関係性への影響
Fenton JJ, Duberstein PR, Kravitz RL, Xing G, Tancredi DJ, Fiscella K, et al. Impact of Prognostic Discussions on the Patient-Physician Relationship: Prospective Cohort Study. J Clin Oncol. 2018;36(3):225-30. PMID 29148892.
29.早期緩和ケアによるQOL改善に対するコーピング支援の媒介効果
Greer JA, Jacobs JM, El-Jawahri A, Nipp RD, Gallagher ER, Pirl WF, et al. Role of Patient Coping Strategies in Understanding the Effects of Early Palliative Care on Quality of Life and Mood. J Clin Oncol. 2018;36(1):53-60. PMID 29140772.
30.緊急入院した進行がん患者の退院後療養場所の関連要因
Lage DE, Nipp RD, D'Arpino SM, Moran SM, Johnson PC, Wong RL, et al. Predictors of Posthospital Transitions of Care in Patients With Advanced Cancer. J Clin Oncol. 2018;36(1):76-82. PMID 29068784.
31.小児がんサバイバーの虚血性心疾患と脳卒中のリスク予測スコアの開発
Chow EJ, Chen Y, Hudson MM, Feijen EAM, Kremer LC, Border WL, et al. Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer. J Clin Oncol. 2018;36(1):44-52. PMID 29095680.
32.がん患者の血小板輸血に関するASCOガイドラインの更新
Schiffer CA, Bohlke K, Delaney M, Hume H, Magdalinski AJ, McCullough JJ, et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018;36(3):283-99. PMID 29182495.
33.早期乳がんでのアロマターゼ阻害薬関連関節痛に対するデュロキセチンの無作為比較試験
Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, et al. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol. 2018;36(4):326-32. PMID 29136387.
34.造血幹細胞移植の種類による移植後の認知機能低下の比較
Sharafeldin N, Bosworth A, Patel SK, Chen Y, Morse E, Mather M, et al. Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study. J Clin Oncol. 2018;36(5):463-75. PMID 29252122.
35.脳転移に対する全脳照射の総説
Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V. Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? J Clin Oncol. 2018;36(5):483-91. PMID 29272161.
36.がん患者の性的問題に関するASCOガイドライン(オンタリオ州ガイドラインの採用)
Carter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, et al. Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J Clin Oncol. 2018;36(5):492-511. PMID 29227723.

【Ann Oncol. 2017;28(12), 2018;29(1-4)
37.欧州臨床腫瘍学会ESMOの支持療法・緩和ケアのポジションペーパー
Jordan K, Aapro M, Kaasa S, Ripamonti CI, Scotte F, Strasser F, et al. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol. 2018;29(1):36-43. PMID 29253069.
38.がん臨床での抗うつ薬使用に関する総説
Grassi L, Nanni MG, Rodin G, Li M, Caruso R. The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol. 2018;29(1):101-11. PMID 29272358.
39.BRCA変異乳がんでの妊孕性保存の可能性と効果
Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA, Jr., Desir J, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018;29(1):237-43. PMID 29045555.
40.乳がん化学療法での好中球減少症予防に対するフィルグラスチンのバイオシミラーEP2006の安全性と有効性に関する第V相無作為化比較試験
Blackwell K, Gascon P, Krendyukov A, Gattu S, Li Y, Harbeck N. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2018;29(1):244-9. PMID 29091995.
41.腎臓がんでのソラフェニブによる術後補助療法に関する患者の希望
Blinman PL, Davis ID, Martin A, Troon S, Sengupta S, Hovey E, et al. Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? Ann Oncol. 2018;29(2):370-6. PMID 29177440.
42.限局性前立腺がんのアンドロゲン除去療法でのリウマチ性関節炎のリスク
Yang DD, Krasnova A, Nead KT, Choueiri TK, Hu JC, Hoffman KE, et al. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Ann Oncol. 2018;29(2):386-91. PMID 29267861.
43.去勢抵抗性前立腺がんでの患者報告アウトカムの変化と予後の関連
Cella D, Traina S, Li T, Johnson K, Ho KF, Molina A, et al. Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302. Ann Oncol. 2018;29(2):392-7. PMID 29237083.
44.小細胞肺がん治療での低分子ヘパリンの上乗せ効果に関する第V相無作為化比較試験
Ek L, Gezelius E, Bergman B, Bendahl PO, Anderson H, Sundberg J, et al. Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. Ann Oncol. 2018;29(2):398-404. PMID 29106448.
45.高度催吐性化学療法での化学療法誘発性悪心・嘔吐予防に対するnetupitant/palonosetron 配合薬の第V相無作為化比較試験
Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018;29(2):452-8. PMID 29092012.

【Eur J Cancer. 2017;83-87, 2018;88-90
46.悪性黒色腫でのリンパ浮腫のQOLへの影響
Gjorup CA, Groenvold M, Hendel HW, Dahlstroem K, Drzewiecki KT, Klausen TW, et al. Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema. Eur J Cancer. 2017;85:122-32. PMID 28918186.
47.がん臨床試験の質保証に関するEORTCの意見論文
Members of EQ, Working Groups of Scientific E. Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC). Eur J Cancer. 2017;86:91-100. PMID 28964907.
48.がんの治療開発と実臨床のギャップに関するEORTCの意見論文
Kempf E, Bogaerts J, Lacombe D, Liu L. 'Mind the gap' between the development of therapeutic innovations and the clinical practice in oncology: A proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimise cancer clinical research. Eur J Cancer. 2017;86:143-9. PMID 28987771.
49.Web上での乳がん予後予測スコアPREDICT v 2.0の開発
van Maaren MC, van Steenbeek CD, Pharoah PDP, Witteveen A, Sonke GS, Strobbe LJA, et al. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population. Eur J Cancer. 2017;86:364-72. PMID 29100191.
50.膵管がんによる社会への経済的影響
Gerard C, Fagnoni P, Vienot A, Borg C, Limat S, Daval F, et al. A systematic review of economic evaluation in pancreatic ductal adenocarcinoma. Eur J Cancer. 2017;86:207-16. PMID 29024890.
51.プロテインキナーゼ阻害薬治療中の味覚障害の総説
van der Werf A, Rovithi M, Langius JAE, de van der Schueren MAE, Verheul HMW. Insight in taste alterations during treatment with protein kinase inhibitors. Eur J Cancer. 2017;86:125-34. PMID 28987769.
52.無作為化比較試験と実臨床のギャップを医療ビッグデータで橋渡しする:血液がんでの例
Kibbelaar RE, Oortgiesen BE, van der Wal-Oost AM, Boslooper K, Coebergh JW, Veeger N, et al. Bridging the gap between the randomised clinical trial world and the real world by combination of population-based registry and electronic health record data: A case study in haemato-oncology. Eur J Cancer. 2017;86:178-85. PMID 28992561.
53.高齢がん患者の外科手術後の認知機能低下
Plas M, Rotteveel E, Izaks GJ, Spikman JM, van der Wal-Huisman H, van Etten B, et al. Cognitive decline after major oncological surgery in the elderly. Eur J Cancer. 2017;86:394-402. PMID 29100194.
54.シスプラチンによる脱毛に対するアスピリンの第U相無作為化比較試験(COAST試験)
Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, et al. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. Eur J Cancer. 2017;87:75-83. PMID 29128692.
55.前立腺がん終末期での緩和ケアの医薬品使用:スウェーデンでの全国調査
Lycken M, Drevin L, Garmo H, Stattin P, Adolfsson J, Lissbrant IF, et al. The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data. Eur J Cancer. 2018;88:101-8. PMID 29216521.

【Br J Cancer. 2017;117(11-12), 2018;118(1-4)
56.小児がんサバイバーの長期的な健康状態のリスク予測モデル
Frobisher C, Glaser A, Levitt GA, Cutter DJ, Winter DL, Lancashire ER, et al. Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up. Br J Cancer. 2017;117(11):1723-31. PMID 29065109.

【Cancer. 2017;123(23-24), 2018;124(1-4)
57.入院進行期がん患者の身体・精神症状と医療利用の関連
Nipp RD, El-Jawahri A, Moran SM, D'Arpino SM, Johnson PC, Lage DE, et al. The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer. Cancer. 2017;123(23):4720-7. PMID 29057450.
58.がん治療の有害事象リスクの疫学調査
Lipitz-Snyderman A, Pfister D, Classen D, Atoria CL, Killen A, Epstein AS, et al. Preventable and mitigable adverse events in cancer care: Measuring risk and harm across the continuum. Cancer. 2017;123(23):4728-36. PMID 28817180.
59.進行がん患者の入院中のコードステータスの変化
El-Jawahri A, Lau-Min K, Nipp RD, Greer JA, Traeger LN, Moran SM, et al. Processes of code status transitions in hospitalized patients with advanced cancer. Cancer. 2017;123(24):4895-902. PMID 28881383.
60.乳がん化学療法中の睡眠と倦怠感に対するチベットヨガの無作為化比較試験
Chaoul A, Milbury K, Spelman A, Basen-Engquist K, Hall MH, Wei Q, et al. Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. Cancer. 2018;124(1):36-45. PMID 28940301.
61.急性骨髄性白血病でのQOL評価尺度AML-QOLの開発
Buckley SA, Jimenez-Sahagun D, Othus M, Walter RB, Lee SJ. Quality of life from the perspective of the patient with acute myeloid leukemia. Cancer. 2018;124(1):145-52. PMID 28881384.
62.身体機能の2評価下位尺度PROMIS PFとFACT-G PWBの比較
Kaat AJ, Schalet BD, Rutsohn J, Jensen RE, Cella D. Physical function metric over measure: An illustration with the Patient-Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT). Cancer. 2018;124(1):153-60. PMID 28885707.
63.髄膜腫でのQOL評価
Benz LS, Wrensch MR, Schildkraut JM, Bondy ML, Warren JL, Wiemels JL, et al. Quality of life after surgery for intracranial meningioma. Cancer. 2018;124(1):161-6. PMID 28902404.
64.子宮がん術後の性機能に対する患者教育とリハビリテーションの効果
Bober SL, Recklitis CJ, Michaud AL, Wright AA. Improvement in sexual function after ovarian cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer. Cancer. 2018;124(1):176-82. PMID 28881456.
65.皮膚がんサバイバーケアの提供状況
Benci JL, Minn AJ, Vachani CC, Bach C, Arnold-Korzeniowski K, Hampshire MK, et al. Survivorship care planning in skin cancer: An unbiased statistical approach to identifying patterns of care-plan use. Cancer. 2018;124(1):183-91. PMID 28885696.
66.乳がんサバイバーの認知機能に対する運動療法の無作為化比較試験
Hartman SJ, Nelson SH, Myers E, Natarajan L, Sears DD, Palmer BW, et al. Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study. Cancer. 2018;124(1):192-202. PMID 28926676.
67.小児がん診断後6カ月での親の苦悩のリスク因子
Schepers SA, Sint Nicolaas SM, Maurice-Stam H, Haverman L, Verhaak CM, Grootenhuis MA. Parental distress 6 months after a pediatric cancer diagnosis in relation to family psychosocial risk at diagnosis. Cancer. 2018;124(2):381-90. PMID 28902391.
68.AYA世代若年がん患者の性機能に関する診断後2年間の縦断研究
Acquati C, Zebrack BJ, Faul AC, Embry L, Aguilar C, Block R, et al. Sexual functioning among young adult cancer patients: A 2-year longitudinal study. Cancer. 2018;124(2):398-405. PMID 29149503.
69.東南アジアのがん患者のPTSDに関する診断後4年間の縦断研究
Chan CMH, Ng CG, Taib NA, Wee LH, Krupat E, Meyer F. Course and predictors of post-traumatic stress disorder in a cohort of psychologically distressed patients with cancer: A 4-year follow-up study. Cancer. 2018;124(2):406-16. PMID 29152719.
70.小児非ホジキンリンパ腫の成人サバイバーの認知機能、心理社会アウトカム、QOL
Ehrhardt MJ, Mulrooney DA, Li C, Baassiri MJ, Bjornard K, Sandlund JT, et al. Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma. Cancer. 2018;124(2):417-25. PMID 28915338.
71.進行肺がん患者のホスピス利用の要因
Sullivan DR, Ganzini L, Lapidus JA, Hansen L, Carney PA, Osborne ML, et al. Improvements in hospice utilization among patients with advanced-stage lung cancer in an integrated health care system. Cancer. 2018;124(2):426-33. PMID 29023648.
72.アンドロゲン除去療法を受ける前立腺がん患者の睡眠障害
Gonzalez BD, Small BJ, Cases MG, Williams NL, Fishman MN, Jacobsen PB, et al. Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer. 2018;124(3):499-506. PMID 29072790.
73.HPV陽性中咽頭がんの化学療法後2年間のQOL評価の推移
Hegde JV, Shaverdian N, Daly ME, Felix C, Wong DL, Rosove MH, et al. Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer. 2018;124(3):521-9. PMID 29044458.
74.がん関連倦怠感に対するスウェーデンマッサージ療法の無作為化比較試験
Kinkead B, Schettler PJ, Larson ER, Carroll D, Sharenko M, Nettles J, et al. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer. 2018;124(3):546-54. PMID 29044466.
75.がん検診参加と精神的苦痛の関連
Fujiwara M, Inagaki M, Nakaya N, Fujimori M, Higuchi Y, Kakeda K, et al. Association between serious psychological distress and nonparticipation in cancer screening and the modifying effect of socioeconomic status: Analysis of anonymized data from a national cross-sectional survey in Japan. Cancer. 2018;124(3):555-62. PMID 29076156.
76.小児急性リンパ性白血病の治療後3年間のQOLの推移
Zheng DJ, Lu X, Schore RJ, Balsamo L, Devidas M, Winick NJ, et al. Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer. 2018;124(3):571-9. PMID 29112230.
77.治療抵抗性のフィラデルフィア染色体異常陽性慢性骨髄性白血病患者の長期的なQOL評価
Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, Brummendorf TH, Su Y, et al. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer. 2018;124(3):587-95. PMID 29072772.
78.高齢がん患者のQOL評価に最も影響する要因
Pisu M, Azuero A, Halilova KI, Williams CP, Kenzik KM, Kvale EA, et al. Most impactful factors on the health-related quality of life of a geriatric population with cancer. Cancer. 2018;124(3):596-605. PMID 29250775.
79.非小細胞肺がんでの悪液質症候群に対するアナモレリンの無作為化比較試験
Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018;124(3):606-16. PMID 29205286.
80.ダウン症のある小児白血病患者の長期的な健康状態
Goldsby RE, Stratton KL, Raber S, Ablin A, Strong LC, Oeffinger K, et al. Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report. Cancer. 2018;124(3):617-25. PMID 29105081.
81.日本の医師の緩和ケアの知識と困難感の全国調査:2008年と2015年の比較
Nakazawa Y, Yamamoto R, Kato M, Miyashita M, Kizawa Y, Morita T. Improved knowledge of and difficulties in palliative care among physicians during 2008 and 2015 in Japan: Association with a nationwide palliative care education program. Cancer. 2018;124(3):626-35. PMID 29023634.
82.主要ながんに関する患者対象のNCCNガイドラインの理解に必要な健康リテラシー
Tran BNN, Ruan QZ, Epstein S, Ricci JA, Rudd RE, Lee BT. Literacy analysis of National Comprehensive Cancer Network patient guidelines for the most common malignancies in the United States. Cancer. 2018;124(4):769-74. PMID 29178322.
83.乳がん術後補助療法中の運動と倦怠感・QOLとの関連
Manneville F, Rotonda C, Conroy T, Bonnetain F, Guillemin F, Omorou AY. The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer. Cancer. 2018;124(4):797-806. PMID 29116645.
84.造血幹細胞移植長期サバイバーでのQOL評価尺度SF-36とPROMISの比較
Shaw BE, Syrjala KL, Onstad LE, Chow EJ, Flowers ME, Jim H, et al. PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer. 2018;124(4):841-9. PMID 29072787.
85.成人悪性リンパ腫の長期サバイバーでのアントラサイクリン系薬剤関連の心機能障害のリスク
Armenian SH, Mertens L, Slorach C, Venkataraman K, Mascarenhas K, Nathwani N, et al. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. Cancer. 2018;124(4):850-7. PMID 29112235.
86.前立腺がん患者の臨床試験データからの治療の毒性総合スコア開発の試み
Lee SM, Hershman DL, Miao J, Zhong X, Unger JM, Cheung YKK. Estimating global treatment toxicity burden from adverse-event data. Cancer. 2018;124(4):858-64. PMID 29112232.

Close